parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in proximal tubule cells	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 53	0.91
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 15601

EEFSEC in dopamine neurons, braak-0.30 (p 0.428) → -0.02 (p 0.962)receipt 15609
EEFSEC in microglia, braak-0.24 (p 0.529) → -0.20 (p 0.613)receipt 15608

receipt 15609: EEFSEC in dopamine neurons, braak

power: full sample -0.13 (p 0.597, n 18), 95% CI -0.57 to +0.36. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.16 (p 0.526, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.39 (p 0.105, n 18). could be the mix.
skeptic: leave-one-out range -0.26 to -0.02, sign flips 0; without severely affected donors -0.13 (p 0.597, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EEFSEC in dopamine neurons.

case closed: nothing better to follow up.

receipt 15608: EEFSEC in microglia, braak

power: full sample -0.13 (p 0.609, n 18), 95% CI -0.56 to +0.36. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.17 (p 0.509, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.23 (p 0.365, n 18). could be the mix.
skeptic: leave-one-out range -0.22 to -0.00, sign flips 0; without severely affected donors -0.13 (p 0.609, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for EEFSEC in microglia.

case closed: nothing better to follow up.

loading the receipts